Valuation : Actinium Pharmaceuticals, Inc.

Market Cap 32.38M 27.85M 26.19M 23.91M 44.72M 3.06B 44.87M 311M 120M 1.57B 122M 119M 5B P/E 2026 *
7.36x
P/E 2027 * -1.52x
Enterprise Value 32.38M 27.85M 26.19M 23.91M 44.72M 3.06B 44.87M 311M 120M 1.57B 122M 119M 5B EV / Sales 2026 *
2.78x
EV / Sales 2027 * -
Free-Float
97.66%
Yield 2026 *
-
Yield 2027 * -
15/08 Actinium Pharmaceuticals Expands Manufacturing Capacity for Actimab-A Program CI
15/08 Actinium Pharmaceuticals, Inc. Amends Its Investigational New Drug CI
08/08 Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
03/06 Actinium Pharmaceuticals Presents New Data on Atnm-400 Demonstrating Potent Activity in Prostate Cancer Models Resistant to All Three Approved Androgen Receptor Inhibitors CI
01/06 Actinium Pharmaceuticals, Inc. Appoints Steffen Heeger as Chief Medical Officer CI
01/06 Actinium Pharmaceuticals Presents New Radiochemistry Data Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates CI
30/05 Actinium Pharmaceuticals - receives two Canadian patent allowances for Actimab-A and Iomab-Act programs RE
30/05 Actinium Pharmaceuticals Receives Patent Allowances for Actimab-A and Iomab-Act Programs in Canada CI
09/05 Actinium Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
06/05 Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of Atnm-400 Across Lung and Prostate Cancer and Radioconjugate Optimization CI
23/04 Actinium Pharmaceuticals, Inc. Highlights Transcriptional Reprogramming As Key Mechanism Underpinning Mutation-Agnostic Activity Of Actimab-A In AML CI
23/04 Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models At the 2026 American Association of Cancer Research Annual Meeting CI
07/04 Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for Atnm-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in Aml CI
1 day-1.90%
1 week+0.98%
Current month+0.98%
1 month+29.17%
3 months-4.63%
6 months-14.17%
Current year-24.26%
1 week 1
Extreme 1
1.06
1 month 0.76
Extreme 0.76
1.15
Current year 0.74
Extreme 0.735101
1.53
1 year 0.74
Extreme 0.735101
1.74
3 years 0.74
Extreme 0.735101
10.24
5 years 0.74
Extreme 0.735101
15.12
10 years 0.74
Extreme 0.735101
64.5
Manager TitleAgeSince
Chief Executive Officer 62 09/06/2017
Chief Tech/Sci/R&D Officer - 01/06/2026
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 71 01/01/2008
Chairman 62 01/10/2013
Director/Board Member 68 08/11/2013
Date Insider Type Main position Quantity % Market Cap. Importance
18/8/25 Tax

Chief Executive Officer

120,900 0.3876%
31/3/25 Issuer sale

Chief Financial Officer

706,588 2.2650%
31/3/25 Issuer sale

Chief Executive Officer

2,385,976 7.6484%
Change 5-day change 1-year change 3-year change Capi.($)
-1.90%+0.98%-34.81%-84.01% 32.38M
-0.38%-0.99%+42.69%+100.85% 67.82B
-0.53%-2.44%+33.34%+78.38% 63.22B
-0.31%+3.67%-12.96%+374.95% 27.58B
+0.86%+2.12%-7.74%-13.34% 26.06B
+1.61%-0.49%+26.32%+15.32% 25.38B
+1.14%+0.90%+22.24%-18.50% 19.89B
+1.15%-5.02%+219.82%+379.02% 17.4B
-0.86%-0.73%-7.65%+522.54% 14.95B
-0.20%+8.00%+55.78%+167.98% 14.62B
Average +0.05%+1.70%+33.70%+152.32% 27.7B
Weighted average by Cap. +0.07%+0.90%+36.40%+139.63%

Financials

2026 *2027 *
Net sales 11.67M 10.03M 9.44M 8.61M 16.11M 1.1B 16.16M 112M 43.25M 565M 43.81M 42.86M 1.8B -
Net income 4.91M 4.22M 3.97M 3.62M 6.78M 464M 6.8M 47.06M 18.19M 238M 18.43M 18.02M 757M -31.71M -27.27M -25.65M -23.41M -43.78M -3B -43.93M -304M -118M -1.54B -119M -116M -4.89B
Net Debt - -
Logo Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pioneering the development of targeted radiotherapies to address significant unmet medical needs in oncology. It operates a pipeline of both early and later stage development programs with two novel solid tumor product candidates, ATNM-400 and Actimab-A, with pan-tumor potential; Actimab-A, which is also being developed as a therapeutic backbone for acute myeloid leukemia and myelodysplastic syndrome in partnership with the National Cancer Institute (NCI), and two targeted conditioning agents, Iomab-B for bone marrow transplant and Iomab-ACT for cell & gene therapies. Its solid tumor asset, ATNM-400, targets a novel antigen distinct from PSMA, with demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Its hematology franchise includes Actimab-A, Iomab-B and Iomab-ACT, which are CD45-targeting conditioning agents.
Employees
27
Date Price Change Volume
04/09/26 USD 1.030 -1.90% 54,229
03/09/26 USD 1.050 +5.00% 78,757
02/09/26 USD 1.000 +0.45% 77,574
01/09/26 USD 0.9955 -2.40% 30,066
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.030USD
Average target price
3.500USD
Spread / Average Target
+239.81%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATNM Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!